Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A library license
July 2019
SHARING OPTIONS:

DUNDEE, U.K.—Ubiquigent Limited and Dorian Therapeutics have inked an agreement under which the latter gains access to one of Ubiquigent’s novel small-molecule libraries specifically designed to target deubiquitylase (DUB) enzymes. Though no financial details were released, the agreement stipulates that Dorian will have access to the library as a physical compound collection and a dataset, as Ubiquigent has screened the library for DUB inhibitory activity with its DUBprofiler platform. This should provide Dorian with novel hits to spur drug discovery.
 
“We hope that this is just the beginning of a fruitful partnership, and that together we will make an impact on the way we treat age-associated diseases. DUBs are powerful targets which haven’t been fully explored until now, but we are here to change that,” Dr. Maddalena Adorno, co-founder and CEO of Dorian, said in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.